Register today for a LIVE national broadcast on New Treatment Options for Rare Diseases in the Soft Tissue for March 5th and 6th!

News >

Next Steps in MCL Include Frontline Trials of BTK Inhibitors

Brandon Scalea
Published: Tuesday, Sep 04, 2018

Simon Rule, MD

Simon Rule, MD, PhD
The promising activity BTK inhibitors have shown in patients with relapsed mantle cell lymphoma (MCL) has led to studies investigating these agents in the the frontline setting.

, Rule, professor of Hematology at Plymouth University Medical School, United Kingdom, discussed the current and potential use of BTK inhibitors for the treatment of patients with MCL.

OncLive: What is the typical prognosis for a patient with MCL, and what is the current standard of care?

Rule: The prognosis depends a little bit on whether you're looking at trial-related data or population-based data. The population-based data, of course, is a lot worse than the data we see in trials. The general prognosis is somewhere between 3 and 5 years. For the younger patients, it's clearly a lot better than that. It's a moving target because BTK inhibitors are going to make a huge difference, particularly in the relapsed setting. It is definitely improving, though.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication